These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7836904)

  • 1. Motifs and supermotifs for MHC class II binding peptides.
    Sinigaglia F; Hammer J
    J Exp Med; 1995 Feb; 181(2):449-51. PubMed ID: 7836904
    [No Abstract]   [Full Text] [Related]  

  • 2. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
    Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
    J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mimicry: CLIP, MHC Class II supermotifs and MAIDS.
    Morse HC
    Immunol Today; 1996 Jan; 17(1):47-8. PubMed ID: 8652054
    [No Abstract]   [Full Text] [Related]  

  • 5. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
    Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
    Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of peptide binding to the class II MHC protein I-Ek.
    Kasson PM; Rabinowitz JD; Schmitt L; Davis MM; McConnell HM
    Biochemistry; 2000 Feb; 39(5):1048-58. PubMed ID: 10653650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtle conformational changes induced in major histocompatibility complex class II molecules by binding peptides.
    Chervonsky AV; Medzhitov RM; Denzin LK; Barlow AK; Rudensky AY; Janeway CA
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10094-9. PubMed ID: 9707606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide binding by class I and class II MHC molecules.
    Batalia MA; Collins EJ
    Biopolymers; 1997; 43(4):281-302. PubMed ID: 9316393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
    Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
    Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
    Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
    Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide binding to MHC class I and II proteins: new avenues from new methods.
    Yaneva R; Schneeweiss C; Zacharias M; Springer S
    Mol Immunol; 2010 Jan; 47(4):649-57. PubMed ID: 19910050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-binding motifs for the I-Ad MHC class II molecule: alternate pH-dependent binding behavior.
    Chaves FA; Richards KA; Torelli A; Wedekind J; Sant AJ
    Biochemistry; 2006 May; 45(20):6426-33. PubMed ID: 16700553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The accessibility of peptides bound to the mouse MHC class II molecule IEd studied by fluorescence.
    de Kroon AI
    FEBS Lett; 1994 Apr; 342(3):230-4. PubMed ID: 8150076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the Affinity of Peptides to Major Histocompatibility Complex Class II by Scoring Molecular Dynamics Simulations.
    Ochoa R; Laio A; Cossio P
    J Chem Inf Model; 2019 Aug; 59(8):3464-3473. PubMed ID: 31290667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential binding of peptides substituted at a putative C-terminal anchor residue to I-Ag7beta56Hisbeta57Ser and I-Ag7beta56Probeta57Asp.
    Oiso M; Matsushita S; Nishi T; Ishikawa T; Nakano N; Yoshida K; Kikutani H; Nishimura Y
    Immunogenetics; 1998 Apr; 47(5):411-4. PubMed ID: 9510560
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).
    Zhong G; Castellino F; Romagnoli P; Germain RN
    J Exp Med; 1996 Nov; 184(5):2061-6. PubMed ID: 8920896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
    Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
    Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.